• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19.

作者信息

Rappaport Stephen H, Clark Jenna M, Delibert Samantha, Maynard Kaylee M, Prasad Paritosh, Kaufman David C, Pietropaoli Anthony P, Quill Caroline M, Groth Christine M

机构信息

University of Rochester Medical Center Rochester, New York.

出版信息

Am J Respir Crit Care Med. 2020 Dec 15;202(12):1731-1733. doi: 10.1164/rccm.202006-2511LE.

DOI:10.1164/rccm.202006-2511LE
PMID:32931713
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7737599/
Abstract
摘要

相似文献

1
Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19.新冠病毒感染中中等剂量血栓预防的抗Xa因子活性
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1731-1733. doi: 10.1164/rccm.202006-2511LE.
2
Reply to Rappaport : Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19.对拉帕波特的回复：新冠病毒病中中等剂量血栓预防的抗Xa因子活性
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1733-1734. doi: 10.1164/rccm.202007-2913LE.
3
Intermediate dose thromboprophylaxis in SARS-CoV-2 related venous thrombo embolism.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）相关静脉血栓栓塞症的中等剂量血栓预防
Eur J Intern Med. 2021 Jun;88:141-143. doi: 10.1016/j.ejim.2021.03.025. Epub 2021 Mar 26.
4
[Recommendations for the use of thromboprophylaxis in hospitalized patients with COVID-19 in Argentina].[阿根廷COVID-19住院患者血栓预防用药建议]
Medicina (B Aires). 2020;80 Suppl 3:65-66.
5
Management of perioperative thromboprophylaxis for surgery following COVID-19: an expert-panel survey.COVID-19后手术围手术期血栓预防管理：专家小组调查
Br J Anaesth. 2021 Oct;127(4):e143-e145. doi: 10.1016/j.bja.2021.06.041. Epub 2021 Jul 9.
6
Venous Thromboembolism and Its Association with COVID-19: Still an Open Debate.静脉血栓栓塞症及其与 COVID-19 的关联：仍存在争议。
Medicina (Kaunas). 2020 Sep 27;56(10):506. doi: 10.3390/medicina56100506.
7
A matter of time: duration and choice of venous thromboprophylaxis in patients diagnosed with COVID-19.时间问题：COVID-19确诊患者静脉血栓预防的持续时间和选择
Br J Hosp Med (Lond). 2020 May 2;81(5):1-2. doi: 10.12968/hmed.2020.0210. Epub 2020 May 18.
8
Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines.COVID-19 相关静脉血栓栓塞症：已报告风险和现行指南的系统综述。
Swiss Med Wkly. 2020 Jun 21;150:w20301. doi: 10.4414/smw.2020.20301. eCollection 2020 Jun 15.
9
In-hospital fatality and venous thromboembolism during the first and second COVID-19 waves at a center opting for standard-dose thromboprophylaxis.在一家选择标准剂量血栓预防措施的中心，第一波和第二波新冠疫情期间的院内死亡率和静脉血栓栓塞情况。
Thromb Res. 2021 Jul;203:82-84. doi: 10.1016/j.thromres.2021.04.026. Epub 2021 May 1.
10
Finding the Optimal Thromboprophylaxis Dose in Patients With COVID-19.寻找新冠病毒疾病患者的最佳血栓预防剂量
JAMA. 2021 Apr 27;325(16):1613-1615. doi: 10.1001/jama.2021.4295.

引用本文的文献

1
Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019.抗 Xa 定向抗栓预防 2019 年冠状病毒病危重症患者血栓形成。
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221116350. doi: 10.1177/10760296221116350.

本文引用的文献

1
Thromboprophylaxis in COVID-19: Anti-FXa-the Missing Factor?2019冠状病毒病的血栓预防：抗Xa因子——缺失的因素？
Am J Respir Crit Care Med. 2020 Aug 1;202(3):455-457. doi: 10.1164/rccm.202005-1654LE.
2
Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019.严重 COVID-19 高凝状态下常规静脉血栓栓塞预防可能不足。
Crit Care Med. 2020 Sep;48(9):e783-e790. doi: 10.1097/CCM.0000000000004466.
3
Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19.科学与标准化委员会通讯：新型冠状病毒肺炎住院患者静脉血栓栓塞症诊断、预防及治疗的临床指南
J Thromb Haemost. 2020 Aug;18(8):1859-1865. doi: 10.1111/jth.14929.
4
Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum.COVID-19 大流行期间的血栓栓塞和抗凝治疗：抗凝论坛的临时临床指南。
J Thromb Thrombolysis. 2020 Jul;50(1):72-81. doi: 10.1007/s11239-020-02138-z.
5
COVID-19 update: Covid-19-associated coagulopathy.新型冠状病毒肺炎最新情况：新型冠状病毒肺炎相关凝血病
J Thromb Thrombolysis. 2020 Jul;50(1):54-67. doi: 10.1007/s11239-020-02134-3.
6
Venous Thromboembolism and Heparin Use in COVID-19 Patients: Juggling between Pragmatic Choices, Suggestions of Medical Societies and the Lack of Guidelines.2019冠状病毒病患者的静脉血栓栓塞与肝素使用：在实际选择、医学协会建议及缺乏指南之间权衡
J Thromb Thrombolysis. 2020 Jul;50(1):68-71. doi: 10.1007/s11239-020-02125-4.
7
High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.抗凝治疗的重症 COVID-19 患者中静脉血栓栓塞事件发生率高。
J Thromb Haemost. 2020 Jul;18(7):1743-1746. doi: 10.1111/jth.14869. Epub 2020 May 27.
8
Anti-Xa assays: What is their role today in antithrombotic therapy?抗 Xa 测定：它们在今天的抗血栓治疗中扮演什么角色？
Cleve Clin J Med. 2019 Jun;86(6):417-425. doi: 10.3949/ccjm.86a.18029.
9
If some is good, more is better: An enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis.如果适量有益，更多则更佳：一种改善药物性静脉血栓栓塞预防的依诺肝素给药策略。
J Trauma Acute Care Surg. 2016 Dec;81(6):1095-1100. doi: 10.1097/TA.0000000000001142.
10
The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis.低分子量肝素血栓预防的抗Xa因子范围
Hematol Rep. 2015 Nov 23;7(4):5844. doi: 10.4081/hr.2015.5844.